



## Aprea strengthens its board

**Stockholm, Sweden – December 22, 2011. Aprea AB announces that Peter Buhl Jensen has been elected as a new member of the board. Peter Buhl Jensen is Professor in Clinical Oncology at Copenhagen University, MD, DMSc and former Chief Oncologist at the Department of Oncology, Ålborg Hospital.**

“We are pleased to welcome Dr. Buhl Jensen to the board”, says Wenche Rolfsen, Chairman of Aprea AB. “His extensive development experience within oncology from the pharmaceutical- and biotechnology industries will be a great benefit to the company as we move forward.”

Peter Buhl Jensen is a co-founder of the Danish cancer therapeutics company Topotarget for which he also was CEO between 2001 and 2010. Peter Buhl Jensen is currently CEO for LiPlasome Pharma ApS and Board Director of Vecata A/S, Mirrx A/S, PledPharma AB, Copenhagen University Proof of Concept financing board, Symbion A/S and WNT Research AB. He has published more than 100 scientific papers on drug development within oncology.

### **For further information, please contact:**

Ulf Björklund, CEO

Aprea AB

Phone: +46 (0)8 50884504

ulf.bjorklund @ aprea.com

### **TO THE EDITORS**

#### **About Aprea**

Aprea AB is a Swedish biotech company focusing on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. Aberrations in p53 are common in many various cancer forms and are associated with increased resistance to standard chemotherapy and thus poor prognosis. Aprea is a Karolinska Development AB (publ) portfolio company. The other main owners are Industrifonden, Östersjöstiftelsen, Praktikerinvest and KD Co-Investment Fund KB. [www.aprea.com](http://www.aprea.com)

#### **About APR-246**

APR-246 has been developed based on results from researchers at Karolinska Institutet. The researchers have discovered that the substance is more efficacious in cancer cells than normal cells, which indicates that it could produce significantly fewer side effects than conventional cancer treatments. By reactivating the tumor suppressor protein p53 the compound induces the cellular suicide program that eliminates the cancer cells. This has been shown in both *in vitro* laboratory studies and animal *in vivo* studies with good results. A unique characteristic of the substance is that it can activate p53 even when the gene is mutated. Cancers with mutated p53 are often more resistant to conventional treatment.